eBiomarker and clinical response of oral cavity squamous cell carcinoma to the MEK 1/2 inhibitor trametinib: A phase II neoadjuvant window of opportunity clinical trial

This article has no abstract
Epistemonikos ID: d0a5b8e86d7afa603adc593d965aabf41f28570c
First added on: Feb 08, 2025